Changes of shear-wave velocity by interferon-based therapy in chronic hepatitis C

Table 3 Characteristics of genotype1 patients studied

	All	SVRs	Relapsers and NVRs	P value
Number of patients	57	17	40
Gender (female/male)	34/23	7/10	25/15	NS
Age (yr)	59 (50-66)	51 (41-58)	62 (54-67)	0.0016
Fibrosis stage (F0-F2 /F3,4)1	25/17	12/0	13/17	< 0.0001
Inflammatory grade (A0,1/A2,3)1	16/26	6/6	10/20	NS
Platelet count (× 104/μL)	14.0 (10.7-18.3)	15.4 (13.0-19.5)	13.2 (9.4-17.4)	NS
Prothrombin time (%)	99 (91-111)	102 (91-110)	98 (92-112)	NS
Albumin (g/dL)	4.2 (4.0-4.5)	4.4 (4.2-4.6)	4.2 (4.0-4.4)	0.0496
Total bilirubin (mg/dL)	0.8 (0.6-1.0)	0.8 (0.5-1.1)	0.8 (0.6-1.0)	NS
AST (IU/L)	47 (32-71)	38 (28-63)	48 (35-77)	NS
ALT (IU/L)	50 (35-90)	50 (30-92)	52 (36-91)	NS
γ-GTP (IU/L)	33 (22-51)	37 (15-66)	30 (23-50)	NS
ALP (U/L)	267 (212-379)	246 (187-262)	314 (215-416)	0.0053
Hyaluronic acid (ng/mL)	95 (46-173)	51 (21-98)	114 (68-180)	0.0076
HCV RNA (logIU/mL)	6.4 (5.8-7.0)	6.0 (5.2-7.1)	6.4 (6.1-6.9)	NS
APRI	0.91 (0.56-1.69)	0.80 (0.45-1.09)	1.05 (0.63-1.73)	NS
FIB-4	2.69 (1.64-4.46)	1.66 (1.26-2.53)	3.34 (2.23-4.63)	0.0014
Vs (m/s); Before treatment	1.44 (1.17-1.75)	1.28 (1.04-1.40)	1.56 (1.20-1.83)	0.0142

¹Fibrosis stage and Inflammatory grade performed by a χ² testing. Comparison between SVRs and non-SVRs (Relapser/NVRs). Data are shown as median (interquartile range). AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; γ-GTP: γ-glutamyltranspeptidase; ALP: Alkaline Phosphatase; APRI: Aminotransferase-to-platelet ratio index; FIB-4: Fibrosis-4; NVR: Non-virological responders; SVR: Sustained virological responder.